Uso del etanercept, un inhibidor del Factor de Necrosis Tumoral | 21 AGO 02
Tratamiento de la espondilitis anquilosante
El tratamiento con etanercept durante cuatro meses produjo una mejoría rápida, significativa y sostenida en los pacientes con espondilitis anquilosante.
Autor: Dres. Gorman JD, Sack KE, Davis JC Jr Fuente: Division of Rheumatology, University of California, San Francisco 94143, USA. N Engl J Med 2002 May 2;346(18):1349-56
1. Wilkinson M, Bywaters EGL. Clinical features and course of ankylosing spondylitis: as seen in a follow-up of 222 hospital referred cases. Ann Rheum Dis 1958;17:209-228.[ISI]
2. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis -- results from the German rheumatological database. J Rheumatol 2000;27:613-622.[ISI][Medline]

3. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766-771.[ISI][Medline]

4. Kennedy LG, Edmunds L, Calin A. The natural history of ankylosing spondylitis: does it burn out? J Rheumatol 1993;20:688-692.[ISI][Medline]

5. Ringsdal VS, Andreasen JJ. Ankylosing spondylitis -- experience with a self administered questionnaire: an analytical study. Ann Rheum Dis 1989;48:924-927.[Abstract]

6. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-255.[ISI][Medline]

7. Taylor AL, Balakrishnan C, Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998;41:1119-1125.[ISI][Medline]

8. Goodacre JA, Mander M, Dick WC. Patients with ankylosing spondylitis show individual patterns of variation in disease activity. Br J Rheumatol 1991;30:336-338.[ISI][Medline]

9. Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998;56:225-240.[ISI][Medline]

10. Gratacós J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-931.[ISI][Medline]

11. Toussirot E, Lafforgue P, Boucraut J, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994;13:175-180.[ISI][Medline]

12. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996;39:1703-1710.[ISI][Medline]

13. Cañete JD, Llena J, Collado A, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997;36:38-42.[ISI][Medline]

14. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.[ISI][Medline]

15. Crew MD, Effros RB, Walford RL, Zeller E, Cheroutre H, Brahn E. Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998;18:219-225.[ISI][Medline]

16. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259.[Abstract/Full Text]

17. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-769.[Abstract/Full Text]

18. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-390.[ISI][Medline]

19. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-486.[ISI][Medline]

20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368.[ISI][Medline]

21. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. J Rheumatol 1999;26:951-954.[ISI][Medline]

22. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-2285.[ISI][Medline]

23. Dougados M, Gueguen A, Nakache JP, Nguyen M, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988;15:302-307.[ISI][Medline]

24. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.[ISI][Medline]

25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.[ISI][Medline]

26. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.[Abstract]

27. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Departmentof Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-2012.[ISI][Medline]

28. The Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965;8:302-334.[ISI]

29. Moll JM, Wright V. An objective clinical study of chest expansion. Ann Rheum Dis 1972;31:1-8.[ISI][Medline]

30. Viitanen JV, Kokko ML, Heikkilä S, Kautiainen H. Neck mobility assessment in ankylosing spondylitis: a clinical study of nine measurements including new tape methods for cervical rotation and lateral flexion. Br J Rheumatol 1998;37:377-381.[ISI][Medline]

31. Arbuck SG, Ivy SP, Setser A, et al. The revised Common Toxicity Criteria: version 2.0. Bethesda, Md.: Cancer Therapy Evaluation Program, 1999. (Accessed March 28, 2002, at

32. Conover WJ. Practical nonparametric statistics. New York: John Wiley, 1980:493.

33. Creemers MC, van Riel PL, Franssen MJ, van de Putte LB, Gribnau FW. Second-line treatment in seronegative spondylarthropathies. Semin Arthritis Rheum 1994;24:71-81.[ISI][Medline]

34. Steven MM, Morrison M, Sturrock RD. Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial. J Rheumatol 1985;12:735-737.[ISI][Medline]

35. Roussou E, Kennedy LG, Garrett S, Calin A. Socioeconomic status in ankylosing spondylitis: relationship between occupation and disease activity. J Rheumatol 1997;24:908-911.[ISI][Medline]

36. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602.[Abstract/Full Text]

37. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-1352.[ISI][Medline]

38. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-1614.[ISI][Medline]

39. Brandt J, Alten R, Burmester G, et al. Three months results of a double-blind placebo controlled, phase-III clinical trial of infliximab in active ankylosing spondylitis. Ann Rheum Dis 2001;60:Suppl 1:61-61.abstract[Abstract/Full Text]

40. McEwen C, DiTata D, Lingg C, Porini A, Good A, Rankin T. Ankylosing spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter's disease: a comparative study. Arthritis Rheum 1971;14:291-318.[ISI][Medline]

41. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 1998;57:135-140.[Abstract/Full Text]

42. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996;8:275-287.[Medline]

43. González S, Martínez-Borra J, López-Larrea C. Immunogenetics, HLA-B27 and spondyloarthropathies. Curr Opin Rheumatol 1999;11:257-264.[Medline]

44. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Siegel JN. Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy. Arthritis Rheum 2000;43:Suppl:S228-S228.abstract[ISI]


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí